SRR820256
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.479
- INFLAMMATORY_RESPONSE+0.470
- TNFA_SIGNALING_VIA_NFKB+0.455
- ALLOGRAFT_REJECTION+0.436
- ANGIOGENESIS+0.424
- COAGULATION+0.411
- HYPOXIA+0.403
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.402
- CHOLESTEROL_HOMEOSTASIS+0.358
- IL2_STAT5_SIGNALING+0.347
Top 10 suppressed
- DNA_REPAIR-0.384
- MITOTIC_SPINDLE-0.248
- MYC_TARGETS_V2-0.233
- G2M_CHECKPOINT-0.222
- WNT_BETA_CATENIN_SIGNALING-0.208
- E2F_TARGETS-0.192
- OXIDATIVE_PHOSPHORYLATION-0.154
- NOTCH_SIGNALING-0.149
- UV_RESPONSE_DN-0.050
- APICAL_JUNCTION-0.034
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR663693 | GTEX | — | 0.915 |
| 2 | SRR1440356 | GTEX | — | 0.904 |
| 3 | sclcM1201764A_S68.txt | — | cohortMD2 | 0.904 |
| 4 | SRR1374414 | GTEX | — | 0.897 |
| 5 | BS_1TPWFSK6 | subependymal giant cell astrocytoma(SEGA) | — | 0.896 |
| 6 | MNG553 | — | — | 0.894 |
| 7 | SRR1347688 | GTEX | — | 0.894 |
| 8 | SRR1323196 | GTEX | — | 0.891 |
| 9 | SRR33532823 | — | C | 0.891 |
| 10 | SRR1445514 | GTEX | — | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.479 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.455 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.436 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.424 | Remibrutinib | — uncovered |
| COAGULATION | 0.411 | Binimetinib | — uncovered |
| HYPOXIA | 0.403 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.402 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.358 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.347 | Idelalisib | — uncovered |
| APOPTOSIS | 0.346 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.346 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.345 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.345 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.343 | Inavolisib | — uncovered |
| COMPLEMENT | 0.342 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.317 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.315 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.307 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.302 | Idelalisib | — uncovered |